Anyone interested in Myovant Sciences Ltd. (NYSE:MYOV) should probably be aware that the General Counsel & Secretary, Matthew Lang, recently divested US$296k worth of shares in the company, at an average price of US$15.55 each. The eyebrow raising move amounted to a reduction of 35% in their holding.
Myovant Sciences Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by the Chief Financial Officer, Frank Karbe, for US$306k worth of shares, at about US$15.55 per share. That means that an insider was selling shares at around the current price of US$15.52. While we don’t usually like to see insider selling, it’s more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it’s not too bad (but it’s still not a positive). Notably Frank Karbe was also the biggest buyer, having purchased US$118k worth of shares.
Over the last year, we can see that insiders have bought 13.00k shares worth US$118k. But they sold 41564 for US$650k. All up, insiders sold more shares in Myovant Sciences than they bought, over the last year. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Does Myovant Sciences Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Myovant Sciences insiders own about US$28m worth of shares. That equates to 2.0% of the company. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Myovant Sciences Insiders?
Insiders haven’t bought Myovant Sciences stock in the last three months, but there was some selling. And our longer term analysis of insider transactions didn’t bring confidence, either. Insiders own shares, but we’re still pretty cautious, given the history of sales. We’re in no rush to buy! Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Myovant Sciences.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.